REPL is one of three companies open in full. Every company in our coverage universe has a Thesis like this one.
Sign up freeMarket reactionShares rose 11% on Nov 2.
Replimune sells TUDRIQEV, which has U.S. accelerated approval for melanoma that progressed after anti-PD-1 therapy and launched on October 1, 2026; its second program, RP2, for uveal melanoma, is not approved.
TUDRIQEV's accelerated approval now has early commercial traction, with more than 15 institutions prescribing it. Durable adoption and IGNYTE-3 survival confirmation remain central. Updated cash includes equity proceeds and a debt draw; management expects funding for greater than twelve months, but funding through the expected 2030 confirmatory readout remains uncertain. RP2 adds a separate opportunity in metastatic uveal melanoma through registration-directed REVEAL, with its Phase 2/3 transition expected in Q1 2027.
Thesis checklist
1 risk needs attention
More than 15 institutions have prescribed TUDRIQEV, and leading melanoma institutions have started treating patients. Initial adoption remains supported; the filing's absence of sales through September precedes the commercial launch.
What would weaken it
IGNYTE-3 remains actively enrolling TUDRIQEV plus nivolumab versus physician's choice. Overall survival is the primary endpoint, with readout expected in 2030; verification of clinical benefit remains central to continued approval.
What would weaken it
Equity proceeds and a debt draw support current operations and alleviated going-concern doubt. Conditional guidance remains greater than twelve months; substantial additional capital needs leave funding through the expected 2030 confirmatory results uncertain.
What would weaken it
REVEAL continues enrolling metastatic uveal melanoma patients, comparing RP2 plus nivolumab with ipilimumab plus nivolumab. Its progression-free-survival and overall-survival endpoints remain the basis for assessing the program's approval opportunity.
What would weaken it
Next decision point
Tests: RP2 earns a path to approval in uveal melanoma
Does REVEAL advance as planned toward survival results in metastatic uveal melanoma?
Progress would support execution of RP2's registration-directed program, a separate opportunity beyond TUDRIQEV.
| Outcome | Evidence to look for | Checklist effect |
|---|---|---|
| Advances as planned | The company reports the planned transition and continued progress toward REVEAL's survival analyses. | Checklist effect:Would support RP2 development execution while clinical benefit awaits survival results. |
| Enrollment update only | The company continues to report enrollment without a transition decision or survival results. | Checklist effect:Would leave RP2's approval opportunity dependent on further clinical progress. |
| Transition delayed or halted | The company reports a delay or halt to the planned transition. | Checklist effect:Would put RP2's development timeline and registration opportunity in doubt. |
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Patient treatment and institutional prescribing provide the first substantive adoption signals beyond commercial availability.
Early prescribing supports adoption, and the equity offering alleviated going-concern doubt. Funding through confirmatory survival results remains uncertain: management provides conditional operating guidance, while the filing says substantial additional funds will be needed.
Source ↗TUDRIQEV (RP1 plus nivolumab) became commercially available in the U.S. for advanced melanoma on October 1, following its August 6 accelerated approval; providers can order it for next-day delivery.
Funding still does not reach the 2030 confirmatory readout. Availability is not yet adoption, and confirmatory survival data are years away.
Source ↗TUDRIQEV received FDA accelerated approval on August 6, 2026 for unresectable advanced cutaneous melanoma after progression on anti-PD-1 therapy, based on a 24.2% ORR and 14.1-month median duration of response in 91 efficacy-evaluable patients.
Approval established a commercial path, but funding through the 2030 confirmatory readout underpinning this assessment has not been established. Launch uptake could change that funding outlook; the stated runway is conditional guidance, not an exhaustion date.
Source ↗FDA advisory committee endorsed RP1 plus nivolumab for advanced melanoma based on IGNYTE Phase 2 data showing 33.6% ORR in anti-PD-1 resistant patients.
The 10–3 advisory vote supported approval despite FDA staff criticism of the single-arm evidence; the recommendation was nonbinding and the agency decision remained pending.
Source ↗KIMMTRAK (tebentafusp, Immunocore) is the only approved systemic therapy with a survival benefit in HLA-A*02:01-positive metastatic uveal melanoma patients, administered intravenously once weekly in a biomarker-selected population. RP2 plus nivolumab, delivered by intratumoral injection, is being evaluated in an unselected population in REVEAL, which could address patients ineligible for or progressing after KIMMTRAK, but Phase 1 data showing a pooled uveal melanoma ORR of 33.3% from an uncontrolled cohort cannot establish whether RP2 improves on tebentafusp outcomes. The Q1 2027 REVEAL Phase 2/3 transition PFS analysis is the evidence event that will determine whether RP2 can carve out a differentiated or complementary position.
| Product | Target | Administration | Status |
|---|---|---|---|
Company product TUDRIQEV RP1 · Replimune | — | intratumoral | Approved |
| Approved | |||
Amtagvipost-anti-PD-1 lifileucel · Iovance | tumor infiltrating lymphocyte (TIL) therapy | IV · single infusion | Approved |
aldesleukin · Iovance | IL-2 cytokine | IV · 600,000 IU/kg (0.037 mg/kg) every 8 hours | Approved |
Imlygic talimogene laherparepvec · Amgen | Oncolytic viral therapy | intralesional · every 2 weeks | Approved |
Keytruda Qlex pembrolizumab and berahyaluronidase alfa-pmph · Merck | PD-1 receptor | SC · every 3 weeks | Approved |
MekinistBRAF V600-mutant trametinib · Novartis | MEK1 and MEK2 | oral · once daily | Approved |
| In development | |||
anzu-celPRAME+ / HLA-A*02:01+; post-PD-1 anzutresgene autoleucel · Immatics | PRAME | IV | Phase 3 |
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.